Second Ebola vaccine to be introduced in the DRC


Health authorities in the Democratic Republic of Congo (DRC) have announced a plan to introduce a second experimental Ebola vaccine, manufactured by Johnson & Johnson (J&J; NY, USA), from mid-October 2019.

The J&J Ebola vaccine is administered in two doses, given 56 days apart, and will be provided to at-risk population in areas that don’t have active Ebola transmission. This strategy will complement the current vaccine (rVSV-ZEBOV-GP, another experimental candidate manufactured by Merck (NJ, USA)), which will continue to be administered to those at high risk of Ebola, including contacts of confirmed cases and contacts of contacts.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment